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Abstract
Background: Acid-sensing ion channels (ASICs) have a significant role in the sensation of pain and constitute an
important target for the search of new antinociceptive drugs. In this work we studied the antinociceptive
properties of the BM-21 extract, obtained from the sea grass Thalassia testudinum, in chemical and thermal models
of nociception in mice. The action of the BM-21 extract and the major phenolic component isolated from this
extract, a sulphated flavone glycoside named thalassiolin B, was studied in the chemical nociception test and in
the ASIC currents of the dorsal root ganglion (DRG) neurons obtained from Wistar rats.
Results: Behavioral antinociceptive experiments were made on male OF-1 mice. Single oral administration of
BM-21 produced a significant inhibition of chemical nociception caused by acetic acid and formalin (specifically
during its second phase), and increased the reaction time in the hot plate test. Thalassiolin B reduced the licking
behavior during both the phasic and tonic phases in the formalin test. It was also found that BM-21 and thalassiolin B
selectively inhibited the fast desensitizing (τ < 400 ms) ASIC currents in DRG neurons obtained from Wistar rats, with
a nonsignificant action on ASIC currents with a slow desensitizing time-course. The action of thalassiolin B shows no
pH or voltage dependence nor is it modified by steady-state ASIC desensitization or voltage. The high concentration
of thalassiolin B in the extract may account for the antinociceptive action of BM-21.
Conclusions: To our knowledge, this is the first report of an ASIC-current inhibitor derived of a marine-plant
extract, and in a phenolic compound. The antinociceptive effects of BM-21 and thalassiolin B may be partially
because of this action on the ASICs. That the active components of the extract are able to cross the blood-brain
barrier gives them an additional advantage for future uses as tools to study pain mechanisms with a potential
therapeutic application.
Background
Acid-sensing ion channels (ASICs) are a group of
sodium-selective ion channels activated by extracellular
acidosis. They are widely expressed in neurons of both
the central and the peripheral nervous system and they
have also been detected in nonneuronal tissues [1-3].
The participation of the ASICs in sensory processes,
synaptic plasticity, learning and memory, and in the sur-
vival of neurons following global ischemia in the brain
has been demonstrated in various animal models [2,4-8].
The role of ASICs in nociception has been shown in dif-
ferent models of pain and inflammatory hyperalgesia
[9,10]. The cutaneous pain produced in humans by
moderate pH (up to 6) is largely mediated by the ASICs
[11,12] The pain sensation produced by cardiac ischemia
seems also to be mediated by ASIC activation [13].
The search for new selective pharmacological agents
with no significant side-effects is an increasing require-
ment for the development of new drugs to be used in
* Correspondence: esoto24@gmail.com
† Contributed equally
2Instituto de Fisiología, Benemérita Universidad Autónoma de Puebla, 14 sur
6301, CU, San Manuel, Puebla, Pue., CP 72570, México
Full list of author information is available at the end of the article
Garateix et al. Molecular Pain 2011, 7:10
http://www.molecularpain.com/content/7/1/10 MOLECULAR PAIN
© 2011 Garateix et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.the treatment of acute and chronic pain. The standar-
dized extract named BM-21 obtained from the sea grass
Thalassia testudinum, a marine plant highly abundant
along the coasts of Cuba, has been characterized and
patented [14]. This product is rich in flavonoid com-
pounds and it does not possess any known toxicity, but
has antiinflammatory and antioxidant properties and
contributes to the recovery of irradiation-damaged der-
mis and the normal properties of the epidermis [15,16].
The bioassay-guided fractionation of the plant extract
resulted in the isolation of thalassiolin B (chrysoeriol
7-b-D-glucopyranosyl-2"-sulphate), the most abundant
component of the extract. Its topical application (240 μg
cm
-2) markedly reduced skin UVB-caused damage. Tha-
lassiolin B scavenged the 2,2-diphenyl-2-picrylhydracyl
radical (EC50 = 100 μgm L
-1)s u g g e s t i n gt h a ti tm a y
contribute to the protective effect on the skin of the
crude extract of T. testudinum [17].
In this study we describe the antinociceptive effects of
BM-21 and thalassiolin B on different animal models of
pain, and the inhibitory action of BM-21 and thalassiolin
B on the ASIC currents in isolated dorsal-root ganglion
(DRG) neurons in a primary culture.
Methods
Sea Grass Collection
T. testudinum (Banks ex König, 1805) was collected in
March 2008 from La Concha Beach (22°05’45’’N, 82°
27’15’’W) and identified by Dr. J.A. Areces (Institute of
Oceanology, Havana, Cuba). A voucher sample (No. IdO
039) has been deposited in the herbarium of the Cuban
National Aquarium.
Extraction and Isolation
Whole dry and ground T. testudinum leaves (840 g) were
continuously extracted (three times) with EtOH-H2O
(50:50, v:v) during 24 h at room temperature. The com-
bined extracts were filtered and concentrated under
reduced pressure and a temperature 30 to 40 °C to yield
54 g of crude extract (BM-21). The fractionation of
BM-21 was done by a bioassay-guided protocol, in which
BM-21 was dissolved in water and successively partitioned
with n-hexane, chloroform, and water-saturated n-butanol.
The bioactive n-butanol fraction was then fractionated by
size-exclusion column chromatography (Sephadex LH-20,
EtOH 97%) to give a late-eluting yellow band. This frac-
tion was further purified by semipreparative C18 reversed-
phase HPLC (Phenomenex Luna C18 column, 5 μm,
250 × 10 mm) using a linear gradient of H2O:MeOH from
8 0 : 2 0t o0 : 1 0 0i n3 5m i n( f l o w :3m L / m i n )t oy i e l dp u r e
thalassiolin B. The structure was confirmed by spectro-
scopic analyses (1D and 2D NMR experiments) and com-
parison with the literature data [18].
Quantification of thalassiolin B in the crude extract
Aqueous solutions of thalassiolin B were prepared at nine
concentrations (0.1 to 3.0 mg mL
-1), and 5 μLo fe a c h
was injected into the Waters HPLC instrument (Phenom-
enex Luna C18 column, 5 μm, 150 × 4.60 mm) with a
gradient of H2O: methanol:trifluoroacetic acid (MeOH:
TFA) (flow 1.0 mL/min from 80:20:0.1 to 0:100:0.1) as
the eluent and with the UV detection set at 280 nm.
A standard curve relating concentration to peak area was
generated, and the retention time and absorbance spec-
trum for the compound were recorded. Four replicates of
the T. testudinum water extract were prepared as
described. Following centrifugation, drying, and weighing,
these extracts were brought up to 13 mg/mL in water
and 5 μL of each was injected in the same HPLC condi-
t i o n sa sf o rt h es t a n d a r d .P e a ka r e a sc o r r e s p o n d i n gt o
thalassiolin B were recorded and converted to concentra-
tion by using the standard curve (R = 0.997).
Instrumental analyses
Column chromatography was done using Sephadex
LH-20 (Pharmacia, Sweden). HPLC purification and
quantification of thalassiolin B were made on a Waters
600 system equipped with a Waters 717 plus autosam-
pler, a Waters 996 photodiode array detector, and a
Sedex 55 evaporative light-scattering detector (Sedere,
France). All solvents used for HPLC were Fisher HPLC
grade. The NMR spectra were made on a Bruker Avance
500 MHz spectrometer. Chemical shifts (δ in ppm) are
referenced to the carbon (δC 49.0) and residual proton
(δH 3.31) signals of CD3OD. Low resolution electrospray
ionization (ESI) mass spectra were obtained with a Bru-
ker Esquire 3000 Plus spectrometer in the negative mode.
Studies in vivo
Animals
Experiments were made on male OF-1 mice (25-30 g)
obtained from the National Center for Laboratory Ani-
mals (CENPALAB), Santiago de Las Vegas, La Habana,
Cuba. The animals were adapted to the laboratory con-
ditions for at least one week, with free access to food
and water, with light:dark cycle 12:12 at a constant
room temperature of 20°C and 70% relative humidity.
They were maintained in the experimental soundless
room for at least 1 day before the experiment and with
a restriction of food and water 2 h before it. All
experiments were made between 0800 and 1300. All
procedures were done according to the European Com-
mission guidelines for the use and care of laboratory
animals and approved by the Committee for Animal
Care in Research of the Center. The minimum number
of animals and duration of observation required to
obtain consistent data were used.
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The quantity of BM-21 to be used was daily dissolved in
distilled water. Indomethacin (IMEFA, Havana, Cuba)
was dissolved in 10% Tween 20 (Merck, Darmstadt,
Germany), formaldehyde (Merck) in PBS (BDH Lab
Supplies, UK) and acetic acid (Merck) in water. Amilor-
ide (Sigma-Aldrich, St. Louis MO) and thalassiolin B
were dissolved in polyethylene glycol (Sigma-Aldrich) at
1.5%. Different concentrations of BM-21 and indo-
methacin were administered orally (by intragastric
canulla), whereas 0.01 mL g
-1 body weight of acetic acid,
amiloride, and thalassiolin B were administered intraper-
itoneally or 20 μL of formaldehyde was administered
subcutaneously. Indomethacin, a well-known peripheral
antiinflammatory (cyclooxigenase-1 [COX-1] inhibitor)
and analgesic drug, was used as a positive control in all
the models. The acetic acid and formaldehyde were
used to produce different modalities of pain in the
respective tests.
To study the antinociceptive activity of BM-21, the
following groups and protocols of treatment were used;
Group 1 (control), mice were treated with distilled
water and served as normal vehicle control. Groups 2, 3,
4, 5 and 6 mice were treated with BM-21 (4, 20, 40,
400, and 1000 mg kg
-1). Group 7, animals were treated
with 15 mg kg
-1 indomethacin. Another experimental
series included the study of the effects of both
100 mmol kg
-1 amiloride and 100 mmol kg
-1 thalassiolin
B on the formalin test. Each animal was used once. The
administration of the vehicles used to dissolve the sub-
stances tested showed no significant action in the beha-
vioral tests (data not shown).
Models used for the evaluation of antinociceptive activity
Hot plate test
The hot plate temperature was kept at 54 ± 1°C. The
response was considered in the form of jumping or lick-
ing of the paws. The latency (in seconds) was recorded
before (from two consecutive measurements at intervals
of 30 minutes) and after 90 min following the oral
administration of BM-21 or indomethacin. This time
was selected on the basis of preliminary experiments
u s i n g1 5m gk g
-1 indomethacin showing that at this
time the response reached a maximum, and then tends
to decay. A cut-off time of 20 s was imposed to avoid
damage to the paw. Analgesic activity was expressed as
t h ei n c r e a s ei nr e s p o n s et i m ew i t hr e s p e c tt ot h ec o r r e -
sponding pretreatment control.
Intraperitoneal acetic acid injection “writhing test”
The BM-21 extract, indomethacin, or water were admi-
nistered 90 min before the test. After 85 min of BM-21
or indomethacin administration, mice were injected
intraperitoneally (ip) with an aqueous solution of acetic
acid (0.6%). The number of contortions and stretches in
each mouse was counted for 20 minutes, starting 5 min
after acetic acid injection. The results were expressed as
percentage of change with respect to controls.
Formalin test
Mice were habituated for 30 min in the glass observa-
tion chambers (20 × 20 × 30 cm). After 90 min, BM-21,
thalassiolin B, amiloride, or indomethacin were adminis-
tered. All mice received 20 μL of 5% formalin injected
into the plantar surface of the right hind paw. The total
number of licking-biting of the injected paw during the
acute early phase (0-5 minutes) and the tonic, last phase
(15-30 minutes) after formalin injection were measured.
Evaluation of motor activity
The motor activity of the animals was evaluated in a
rota-rod apparatus. The animals were placed on the
rota-rod (16 and 32 rpm) and the time they remained
on the apparatus was recorded. The cut off time was
2 min. The performance time was measured for control
animals and at 40, 400, and 1000 mg kg
-1 BM-21.
The rota-rod test was made 90 min after BM-21
administration.
Statistical analysis
ANOVA tests and the nonparametric analysis of var-
iance (Kruskal-Wallis, and U Mann-Whitney) tests were
used to evaluate statistical significance. The software
used was SPSS (IBM) and differences between treated
and control groups were considered statistically signifi-
cant when P ≤ 0.05.
Electrophysiological experiments in vitro
To study the effect of BM-21 and of thalassiolin B on
the ASIC current, the whole cell patch-clamp techni-
que was used. For this purpose the DRG neurons from
Wistar rats (P5 to P9) were isolated and cultured
according to the procedure described by Salceda and
coworkers [19].
Cell culture
The rats were anesthetized and killed with an overdose
of sevofluorane. The dorsal root ganglia were isolated
from the vertebral column and incubated (30 min at
37 °C) in Leibovitz L15 medium (L15) (Invitrogen,
Carlsbad, CA) containing 1.25 mg mL
-1 trypsin and 1.25
mg mL
-1 collagenase (both from Sigma-Aldrich, St.
Louis, MO, USA). After the enzyme treatment, the
ganglia were washed 3 times with sterile L15. Cells were
mechanically dissociated using a Pasteur pipette
and then plated on 12-mm × 10-mm glass coverslips
(Corning, Corning, NY) pretreated with poly-D-lysine
(Sigma-Aldrich) and placed onto 35-mm culture dishes
(Corning). Neurons were incubated 4 to 8 h in a humi-
dified atmosphere (95% air, 5% CO2,a t3 7° C )u s i n ga
CO2 water-jacketed incubator (Nuaire, Plymouth, MN)
to allow the isolated cells to settle and adhere to the
coverslips. The plating medium contained L15, with
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10% fetal bovine serum, 2.5 μg/mL fungizone (both
from Invitrogen), 100 U/mL penicillin (Lakeside, Toluca,
Mexico), and 15.8 mM HEPES (Sigma-Aldrich).
Electrophysiological recording
The DRG neurons were incubated 4 to 8 h and the cul-
ture dish with attached cells was mounted on the stage
of an inverted phase-contrast microscope (TMS, Nikon
Co. Tokyo, Japan). Cells were bathed in an external
solution shown in Table 1. Cell voltage responses were
s t u d i e da tr o o mt e m p e r a t u r e( 2 3 - 2 5° C )u s i n ga nA x o -
patch 1D amplifier (Molecular Devices, Union City,
CA). The cells for recording were selected as not
adhered to other cells, to show no neurite outgrowth,
and to have a round soma of regular size. Only cells
showing a distinct peak-response (an initial peak fol-
lowed by sustained current) to acid perfusion were used
for recording. Command-pulse generation and data
sampling were controlled by pClamp 8.0 software
(Molecular Devices) using a 16-bit data-acquisition sys-
tem (Digidata 1320, Molecular Devices). Signals were
low-pass filtered at 5 kHz and digitized at 10 kHz. Patch
pipettes were pulled from borosilicate glass capillaries
(TW120-3; WPI, Sarasota, FL) using a Flaming-Brown
electrode puller (80-PC; Sutter Instruments, San Rafael,
CA). They typically had a resistance of 1 to 3 MΩ when
filled with the intracellular solution (see Table 1). The
series resistance was electronically compensated for by ≈
80%. The digital data were stored in a PC computer for
off-line analysis.
Experimental protocols and data analysis
The ASIC currents were generated by a fast (about 100 ms)
pH change from 7.4 to 6.1 for 5 seconds, by shifting one of
the three outlets of a fast change perfusion system (SF-77B,
Warner Inst., Hamden, CT) while keeping the cell at a
holding potential (Vh) of -60 mV. The time between the
pH step changes was 1 minute to guarantee that the ASIC
current was completely recovered from desensitization.
The transient receptor potential V1 (TRPV1) antagonist
capsazepine (10 μM) (Sigma Chemical Co., St Louis MO)
was added to the extracellular solution (pH 6.1) to avoid
potential activation of the TRPV1 receptor by a drop in
pH. The variables measured to characterize the ASIC cur-
rents were a) maximum peak amplitude, b) current desen-
sitization time-constant (determined by fitting the decay
phase of the current with a single exponential function:
τdes), c) the amplitude at the end of the acid pH pulse
(it was considered a measure of the steady-state current
and normalized in relation to peak current). The BM-21
was coapplied with the pH change to 6.1 whereas the tha-
lassiolin B was preapplied 20 seconds before the pH change
to 6.1 and during the whole pH pulse [20]. The reason for
this difference in application protocol was because thalas-
siolin B produced highly variable results when coapplied
but a consistent effect when it was preapplied. The pH of
the perfusion solution was checked after adding BM-21 or
thalassiolin B so we can discard the possibility of pH
changes caused by them. To characterize the DRG acid-
gated currents, amiloride (10, 30, and 100 μM), Gd
3+
(100 μM ) ,N as u l f a t e ,a n dc h o l i n ec h l o r i d ew e r eu s e d .
The concentration-response relationship was obtained
comparing the effect of BM21 and of thalassiolin B with
its control. The data were fitted with the function Y =
min +( max-min)/(1+(x/EC50)
H), where Y is the pharma-
cological effect of the substance under study, x is the
substance concentration, max and min are the maxi-
mum and the minimum effects, EC50 is the concentra-
tion at which 50% of the effect is obtained and H is the
Hill slope constant. To define the statistical significance
a paired Student’s t-test was used and P ≤ 0.05 was con-
sidered as significant. Experimental data are presented
as the mean ± standard error.
Results
Concentration of thalassiolin B in the crude extract of
Thalassia testudinum
The concentration of thalassiolin B in the crude
extract BM-21 obtained from Thalassia testudinum was
determined. Because thalassiolin B is water soluble and
difficult to isolate quantitatively, it was necessary to
evaluate its concentration by using analytical-scale
HPLC peak integration. Using this method, the concen-
tration of thalassiolin B was equivalent to 5.8 ± 0.3%
(weight) of the crude extract. The HPLC traces of this
compound (standard) and of the crude extract are
shown in Figure 1. The absorbance spectra for the stan-
dard and the corresponding 21-min peak in the extract
were identical, confirming that the compound being
quantified was thalassiolin B. This was also confirmed
by LC-ESIMS analysis which showed the characteristic
ion at m/z 541 ([M-H]
-).
Table 1 Solutions used for voltage clamp recording
Extracellular (mM) pH 6.1
Extracellular (mM)
Intracellular (mM)
NaCl 140 140 10
KCl 5.4 5.4 140
CaCl2 1.8 1.8 0.134
MgCl2 1.2 1.2 -
HEPES 10 - 5
MES -1 0 -
EGTA --1 0
MgATP --2
Na-
GTP
--1
pH 7.4 adjusted
with NaOH
pH 6.1 adjusted
with NaOH
pH 7.2 adjusted
with KOH
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Hot plate test
The BM-21 was used in concentrations ranging from 4 to
1000 mg kg
-1 in the diverse models of nociception. In the
hot plate test, the administration of 4 and 20 mg kg
-1
BM-21 (n = 6 each) produced no significant effect. How-
ever BM-21 (40, 100, 400, and 1000 mg kg
-1; n =1 2
each) and indomethacin (15 mg kg
-1; n = 16) produced a
significant increase in the response latency tested 90 min
after its administration (P ≤ 0.05; Figure 2A), although
the action of 400 and 1000 mg.kg
-1 BM-21 had a lower
amplitude than that produced with 40 mg kg
-1.
Writhing test
The ip injection of acetic acid in control mice produced
51.4 ± 4.1 contortions and stretches (n = 19). The action
of BM-21 and indomethacin were studied 90 min after
their administration. The use of 4 and 20 mg kg
-1
BM-21 (n = 8 each) apparently reduced the number of
contortions and stretches but this reduction was not sig-
nificant (P ≥ 0.05). The use of a higher concentration of
BM-21 (40 mg kg
-1) significantly reduced the number of
contortions and stretches to 26.8 ± 5.7 (47% protection,
n = 12; P = 0.018), and 400 mg kg
-1 BM-21 produced
the maximum reduction in the number of contortions
and stretches; 21.9 ± 3.9 (57% protection; n = 19; P ≤
0.001), whereas at 1000 mg kg
-1 the reduction was 31 ±
3.5 (39% protection; n = 10; P = 0.004) (Figure 2B). In
the experimental group in which 15 mg kg
-1 indometha-
cin was used (n = 12) the number of contortions and
stretches was 8.7 ± 2.1 (83% protection; P ≤ 0.001 com-
pared to control). The action of indomethacin was
apparently greater than the maximum effect of 400 mg
kg
-1 BM-21 but the difference was not significant
(P = 0.19).
Figure 1 Chromatographic profile of BM-21 and structure of the bioactive flavone glycoside. A) Chemical structure of thalassiolin B
(chrysoeriol 7-b-D-glucopyranosyl-2"-sulphate) isolated from T. testudinum. B) HPLC traces of the standard of thalassiolin B. C) HPLC profile of BM-
21. The HPLC conditions to obtain B and C were similar (see ‘Material and Methods’).
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stretches was obtained with 400 mg kg
-1 BM-21, this
dose was used to study the temporal dependence of the
BM 21 effect in the acetic acid-generated contortions
and stretches. The effect of 400 mg kg
-1 BM-21 was sig-
nificant after 60 minutes (34% reduction; P = 0.03) and
a greater reduction of contortions and stretches was
reached after 90 minutes (57% reduction; P = 0.001) of
BM-21 administration (data not shown).
Formalin test
In the formalin-generated licking behavior the adminis-
tration of 4 to1000 mg kg
-1 BM-21 (n = 12 for each
group) had no significant effect on the number of lick-
ings in the 1st-phase (0-5 min) after formalin injection
(Figure 3A). However, in the 2nd phase (15-30 min),
the BM-21 produced a significant effect at concentra-
tions ranging from 20 to 1000 mg kg
-1 The maximum
reduction of 49% in the licking behavior was attained
with the use of 40 mg kg
-1 BM-21. In comparison with
the control group, a one-way ANOVA analysis revealed
a significant effect of the extract in the late phase at
doses of BM-21 from 20 to 1000 mg kg
-1 (Figure 3B).
The use of 15 mg kg
-1 indomethacin produced a signifi-
cant reduction in both the 1st- and 2nd-phase of the
formalin test. The licking behavior during the 1st-phase
was unaffected by 100 mmol kg
-1 amiloride (n =6 ) ,
whereas 100 mmol kg
-1 thalassiolin B (n =6 )d e c r e a s e d
the licking behavior 34% (Figure 3A). Both compounds
reduced the 2nd-phase licking behavior similarly (13 ±
2.2 for amiloride and 11.6 ± 1.4 for thalassiolin B;
Figure 3B).
The actions of BM-21 in the nociception tests used
did not show typical dose response relationships, which
m a yh a v eb e e nc a u s e db yt h en o n s p e c i f i ca c t i o n so f
BM-21. In the work with natural extracts it is common
to find this type of dose relationship. This extract is a
mixture of flavonoids, terpenes, saponins, and other
constituents that could contribute differently to the bio-
logical activity. The antinocioceptive effect of BM-21
results from the combined action of all the pharmacolo-
gically active components of the extract. It would be
possible that the pharmacological action of one or more
compounds could produce opposite effects (pronocicep-
tive action) and at higher concentrations this contribu-
tion could have become more evident in comparison
with other compounds that can reach a plateau at this
concentration, resulting in a decrease of the action of
the BM-21. Considerable mechanistic evidence indicates
that U-shaped dose-response curves are common and
have been designated as hormetic effects, mediated by
agonist concentration gradients with different affinities
for stimulatory and inhibitory regulatory pathways [21].
Figure 2 Effects of BM-21 on the thermal nociception and acetic acid writhing test. A) In the hot plate test the use of BM-21 (40 -
1000 mg kg
-1) and 15 mg kg
-1 indomethacin increased the latency of response measured 90 min after drug administration. Control = 3.3 s
(dotted line). * P ≤ 0.05, ** P ≤ 0.001. In this and following graphs each bar represents mean ± SE, marks * and ** indicate significantly different
from control (P ≤ 0.05, P ≤ 0.001) (one-way ANOVA and Student’s t-tests). B) Number of contortions and stretches generated by the
intraperitoneal injection of acetic acid measured in control and after 90 min of BM-21 or indomethacin administration.
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To discard the possibility that the BM-21 would exert a
sedative action, explaining the effect observed in pre-
vious behavioral tests, studies of the motor activity of
the animals after BM-21 (40, 400, and 1000 mg kg
-1)
were made using the rota-rod test. According to the
data shown in Table 2 (n = 12), BM-21 did not alter the
time that mice spent in the rota-rod apparatus, indicat-
ing that potential changes in the motor activity could
not account for the effects observed in previous
Figure 3 The effect of BM-21 and thalassiolin B on nociception caused by formalin injection into the hind paw. A) No significant effect
of BM-21 or amiloride was observed during the 1st-phase nociception, although indomethacin and thalassiolin B produced a significant
reduction in the number of lickings. B) In the 2nd-phase, except for the lowest dose of the BM-21 (4 mg kg
-1), all the drugs used produced a
significant reduction in the number of lickings. The magnitude of the thalassiolin B action was similar to that of amiloride and apparently larger
than that produced by 15 mg kg
-1 indomethacin, but the difference was not significant (P = 0.302).
Table 2 Rota-Rod motor performance under the influence
of BM-21
Latency
8 rpm 16 rpm 32 rpm
Control 120 120 120
40 mg kg
-1 120 117 ± 2.3 117 ± 1.8
400 mg kg
-1 120 120 ± 0.1 117 ± 2.1
1000 mg kg
-1 120 120 108 ± 7.2
Table shows the latency of the time that mice spent in the rota-rod apparatus in
control and with the use of various BM-21 concentrations (cut-off time was 120 s).
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caused by an antinociceptive effect.
Effects of BM-21 and thalassiolin B in vitro
DRG acid-gated currents
The whole-cell voltage-clamp recordings of acid-gated
currents were obtained on 114 DRG neurons. The mean
membrane-capacitance of the cells was 59 ± 1.3 pF, cor-
responding to an estimated neuron diameter of 43 ±
5 μm. The cells used for the recordings constitute a
relatively restricted population primarily from large-
diameter DRG neurons. The current activated by
acidic-solution perfusion in DRG neurons showed char-
acteristics indicating the participation of diverse ASIC
subunits in the macroscopic current. The acidic-gated
current characteristics found in DRG neurons varied
from a fast transient current with little steady-state cur-
rent, to a current with a clear steady-state, and finally to
a slowly desensitizing current with a large steady-state
component. To demonstrate that the acid-gated currents
that were recorded from the DRG neurons in our
experimental conditions were indeed caused by the acti-
vation of the ASICs, the use of 10, 30, and 100 μM
amiloride produced a concentration dependent 39 ±
3.8% (n =3 ) ,6 7±4 . 5 %( n = 7), and 85 ± 2.3% (n =6 )
reversible inhibition of the proton-gated peak current
(Figure 4A, B, C). Also, the use of 100 μMG d
3+ (n =4 )
produced a significant inhibition of 90 ± 1.3% of the
acid-gated current (Figures 4D). The acid-gated currents
were also studied with the use of an external solution in
which 140 mM NaCl was substituted by 140 mM choline
chloride (n = 5). In this condition the inward current
produced by a pH 6.1 acid solution perfusion was
reduced 96 ± 1% compared to the control, showing that
the proton-gated current was an Na
+ current (Figure 4E).
The curve for the current amplitude versus pH showed
that half of the maximum current (pH50) was attained
at pH 6.12 ± 0.1 (n =7 ;F i g u r e4 F ) .T h e s er e s u l t s
demonstrate that the proton-gated current we are
recording had the typical properties of the ASIC cur-
rents; a proton-gated Na
+ current inhibited by amiloride
and Gd
3+ (both in the μM range).
Based on the pH sensitivity of the ASIC currents we
decided to use a pH of 6.1 to activate the ASIC currents
in the experiments designed to characterize the action
of the BM-21 and thalassiolin B on the ASIC currents
in the DRG neurons. It was possible to distinguish two
main types of acid-gated currents; a fast transient cur-
rent with a complete desensitization or with a small
steady-state current (less than 10% of the peak current),
and a slowly desensitizing current (τ greater than 400 ms).
From their kinetics and desensitization profiles, it was
possible to establish an analogy between the first type
and the respective cloned ASIC1- and ASIC3-like and
the second type as the ASIC2-like [9] (Figure 5A). It was
not possible to find any significant correlation between
the ASIC current characteristics and cell capacitance,
perhaps because other authors used acutely dissociated
instead of cultured cells [9]. The ASIC2-like current was
clearly distinguishable and its incidence was low (about
25% in frequency). However, it was not possible to sepa-
rate ASIC1- and ASIC3-like currents, because the pro-
portion of different channel populations within the same
cell generates a wide range of possible current wave-
forms. So, for practical purposes we classified the ASIC
currents as fast (with a τ < 400 ms) and slowly desensitiz-
ing (with a τ > 400 ms).
None of the substances used in this work produced
any electrophysiological action or any changes in the
holding current by their perfusion alone. This excludes
the possibility that their actions were caused by altera-
tions of the many other ionic currents present in DRG
neurons at -60 mV.
Effect of BM-21 on the ASIC currents
The coapplication of BM-21 with pH 6.1 reduced the
peak amplitude of the rapid desensitizing ASIC currents
in the doses assayed in a concentration-dependent man-
ner. The BM-21 had no significant effect on the ASIC
currents with a slowly desensitizing time-course (τ >
400 ms). At the highest concentration used (10 mg mL
-1)
the amplitude of the of rapid desensitizing (τ < 400 ms)
ASIC current was reduced 56% from 8.1 ± 2.2 nA in the
control to 3.7 ± 1.1 nA (Figure 5B). The concentration
response relationship had an IC50 of 0.72 ± 0.16 mg mL
-1
(n = 4; Figure 5C).There was a no significant tendency to
increase the amplitude of the sustained component by
increasing the BM-21 concentration. The current desen-
sitization rate was not significantly affected (control τ =
231.7 ± 23.3 ms versus τ = 319.6 ± 56.6 ms, P > 0.05 Stu-
dent’s t test, with 10 mg mL
-1 BM-21), and its action was
fully reversible after washing the preparation (between
the first and the second minute) at concentrations below
10 mg mL
-1. However, the maximum current inhibition
of 56% was attained with 10 mg mL
-1 BM-21 and the
reversibility at this dose was 84%.
Effect of thalassiolin B on the ASIC currents
The use of thalassiolin B also produced a significant
reduction of the ASIC-current peak amplitude in those
cells with a fast desensitizing current (τ < 400 ms), with
no significant change in the kinetic characteristics of the
current (Figure 6A). No action was exerted by this com-
pound on the slowly (τ > 400 ms) desensitizing ASIC
currents (n = 8; Figure 6B). The maximum inhibitory
action of thalassiolin B was 30%, from 5.6 ± 1.6 nA
under control conditions to 3.9 ± 1.0 nA in the presence
of 1 mM thalassiolin B. The concentration-effect rela-
tionship for the thalassiolin B-sensitive currents showed
a dose-dependent inhibitory action on the peak-current
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The effect was fully reversible at all the concentrations
used and the maximum current inhibition of about 30%
was attained with 0.1 mM thalassiolin B. The current
desensitization time-constant was not significantly
affected (control τ = 207 ± 11 ms versus τ = 192 ±
14 ms, P >0 . 0 5 ,S t u d e n t ’s t test, with 1 mM thalassiolin B).
Also, the sustained component of the ASIC current was
unaffected.
Because thalassiolin B is a sulfate flavone glycoside, for
a control of the potential effect of sulfate the perfusion
of 0.1 mM sodium sulfate was also studied. No signifi-
cant effect of sodium sulfate on the ASIC current was
found (n = 4; data not shown), indicating that the
observed effects were specifically caused by the molecule
of thalassiolin B.
To study the influence of thalassiolin B on the gating
of the ASIC current, the pH dependence of the current
amplitude was studied in the control and with the use
of 100 μM thalassiolin B. The pH50 in the control was
6.12 ± 0.1 (n = 7) and with the use of thalassiolin B was
6.15 ± 0.1 (n =7 ;P ≥ 0.05; Figure 7A). This result indi-
cates no interaction with the proton gating of the chan-
nel. To further characterize the potential influence of
the occupation of proton-binding sites on the actions of
thalassiolin B, the effects of the drug were studied while
the pH of the bath solution was varied between 7.0 and
8.0 with 0.2 pH increments (steady-state desensitization
curves). The pH of the preconditioning bath produced a
significant effect over the current produced by perfusion
at pH 6.1. The preconditioning pH-effect relationships
were constructed in control (pH50 = 7.19 ± 0.04, n =5 )
Figure 4 The effect of amiloride, Gd
3+, and Na
+-free extracellular solution on the proton-gated current in DRG neurons. A-C) The use of
amiloride produced a concentration-dependent and reversible inhibition of the proton-gated peak current without significantly modifying the
steady-state current. In this and following graphs the black traces represent the control and the drug effect, the gray trace is after washout. The
dotted line shown in this and following current recordings indicates the zero current, and the gray bar the time of pH 6.1 + drug application.
The graphs display the first 3 seconds after the 5-s pH 6.1 perfusion. D) The use of Gd
3+ also produced a reversible inhibition of the proton-
gated current. E) The use of a Na
+-free extracellular solution significantly decreased the current (to 4% of control current) reversibly. F) The
normalized current amplitude versus pH relationship shows a sigmoidal dependence on the pH with a pH50 of 6.12 ± 0.1. Currents were
normalized as a function of the current obtained with pH 4.
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7.27 ± 0.03, n = 7; Figure 7B), indicating that its action
is not dependent on the state, closed or inactivated, of
the ASICs. The relationship between the effect of
100 μM thalassiolin B and the pH used to activate the
ASIC current showed no significant pH dependence (pH
4 n = 22; pH 5 n =8 ;p H6 . 1n =8 ;p H6 . 5n =9 ;
Figure 7C). The interaction of amiloride and thalassiolin B
was also studied. We found that the effect of 100 μM tha-
lassiolin B on the ASIC current activated by pH 6.1
Figure 5 ASIC-current type and effect of BM-21 on the ASIC currents. A) Typical pH-gated currents recorded in DRG cells (pH 6.1, 5 s).
B) The use of 10 mg mL
-1 BM-21 reduced the peak amplitude of the pH-gated current in a reversible form. C) The dose-response relationship of
the BM-21 inhibitory effect on the ASIC currents in the DRG neurons was constructed pulling together cells with a desensitizing τ < 400 ms. The
IC50 was 0.72 ± 0.16 mg mL
-1.
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Figure 7D). Finally, no significant influence of holding
voltage (-20 mV versus -60 mV) on the thalassiolin B
action was observed (n = 4; data not shown).
Discussion
This study demonstrates the antinociceptive action of
BM-21 in the classical pharmacological models of ther-
mal- (hot plate test) and chemical-caused (acetic acid
and formalin tests) pain in mice and of thalassiolin B in
the formalin test. The inhibition of the nociceptive
behavior does not seem to result from a nonspecific
muscle-relaxant or sedative effect because the BM-21
extract did not show any motor performance alterations
in the rota-rod test.
T h eh o tp l a t et e s ti so n eo ft h em o s tc o m m o n l yu s e d
for nociception studies [22]. The increase in tempera-
ture produces two behavioral components (paw licking
and jumping) that can be measured by their reaction
times. In this model, BM-21 significantly increased the
latency for jumping or licking suggesting that the extract
exerts an acute antinociceptive action [23]. The acetic
acid-generated writhing test has been used for the
assessment of analgesic or antiinflammatory properties
of several drugs. Oral administration of BM-21 reduced
contortions and stretches thus indicating it is exerting
an antinociceptive action in persistent tonic pain.
Nociceptive behavior in the formalin test has been
divided into two phases [22,24]. The initial 1st-phase
(nociceptive pain) is considered to be caused predomi-
nantly by activation of C fibers, whereas the 2nd-phase is
associated with inflammatory components with release of
different pain mediators (22,23,24). Reactive oxygen spe-
cies (ROS) have been documented to contribute to and
maintain conditions of chronic pain [25]. Both phases are
sensitive to centrally acting drugs such as opioids [26],
but the 2nd-phase is also sensitive to corticosteroids and
nonsteroidal antiinflammatory drugs (NSAIDs), especially
when the formalin is injected in high concentrations
[26-29]. Antioxidants attenuate both phases of the
responses in mice [25]. It has been established that
COX-1 is involved in the 2nd-phase response in the for-
malin test and in the writhing test in mice [30]. A pre-
vious report has demonstrated the inhibition in vitro of
Figure 6 The effect of thalassiolin B on the ASIC currents. A) Inhibitory action of 0.03 mM thalassiolin B on the ASIC current in a cell with a
τ = 283.3 ms was 23% and fully reversible. B) No significant action of 0.03 mM thalassiolin B was observed in slowly desensitizing ASIC currents.
Current shown has a τ = 984 ms. C) Concentration-response relationship of thalassiolin B inhibitory action on the ASIC currents in DRG neurons.
The continuous line shows a dose-response curve adjustment to the data with an IC50 of 27 ± 2.6 μM.
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BM-21[31]. Thus, the dual effect exerted by BM-21 on
the arachidonic acid pathway could account for its effect
in the 2nd-phase of the formalin test and in the writhing
test. The BM-21 and thalassiolin B also have ROS
scavenging properties. These could contribute to the anti-
nociceptive effects observed in vivo, however in the DRG
experiments in vitro this effect could be minor or absent.
The contribution of ASIC channels in the formalin test
has been documented and consistently both amiloride
and thalassiolin B attenuated painful behavior in the late
phase. For amiloride our data show similarities with
those reported in the literature [32]. Albeit it has been
found that amiloride use in the formalin test attenuated
the 2nd-phase in female, but not in male, CD 1 mice
(except at a toxic dose) [33]. The effect of BM-21 on
both the formalin and writhing tests support that its pro-
file is consistent with antiinflammatory analgesic drugs,
however a phasic-antinociceptive action is also produced,
particularly bearing in mind the antinociceptive effects of
BM-21 on the hot plate model and the effect of thalassio-
lin B on the first phase of the formalin test.
Regalado and coworkers determined that the phenolic
content in BM-21 was 18 ± 1.5% [17]. Consistent with
this, the separation procedure of the plant extract
resulted in the isolation of thalassiolin B as the major
phenolic constituent of the extract. Phenolic com-
pounds, and particularly flavonoids, have a wide variety
of biological activities in mammals [34,35]. Our results
indicate that flavonoids, in particular thalassiolin B, may
contribute in a significant degree to the biological action
of BM-21. In fact, the studies in vivo using the formalin
Figure 7 The effect of thalassiolin B on the pH versus amplitude and steady state desensitization curve of the ASIC current.A )N o
significant influence of 100 μM thalassiolin B on the pH dependence of the ASIC current amplitude was found. B) The use of thalassiolin B also
did not significantly modify the steady-state desensitization of ASIC currents. C) Analysis of the thalassiolin B effect as function of pH used to
activate the current shows no significant correlation (P > 0.05). Line shows the linear regression (slope = 0.27); dotted lines show confidence
intervals at P ≤ 0.05. D) Amiloride (30 μM) decreased the current 64 ± 4%. The coapplication of 30 μM amiloride and 100 μM thalassiolin B
produced an additional nonsignificant 10.8 ± 3.8% decrease of the current (P ≥ 0.05 Student’s t-test; thalassiolin B preapplied 20 s before
coapplication of amiloride and thalassiolin B). Effects were fully reversible.
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antinociceptive action.
Some mechanisms of nociception are known to
involve ASICs [2]. Previous results have documented
that they sense extracellular acidifications occurring dur-
ing inflammation and their expression is increased in rat
sensory neurons (particularly ASIC3) in this pathological
condition [10]. Thus, in an attempt to characterize the
mechanism through which the BM-21 exerts its antino-
ciceptive action we evaluated BM-21 and thalassiolin B
on ASIC currents.
We found that both BM-21 and thalassiolin B were
able to decrease the peak amplitude of ASIC currents;
indicating that, most probably, the effect of BM-21 on
ASIC currents may be because of the presence of thalas-
siolin B. The maximum effect of BM-21 and thalassiolin
B on ASICs currents was about 56% and 30%. Therefore
the activity of thalassiolin B could not account for the
overall activity of the extract, which suggests that other
components are also able to act on the ASIC currents.
The presence of other molecules in the extract and in
particular of thalassiolins A and C could contribute to
this synergic effect [18].
The thalassiolin B inhibitory action on ASIC currents
in DRG neurons was selective, acting only in those neu-
rons with a fast desensitization time-course, without
significant effect on those currents with a slow desensi-
tizing time-course, the so-called “ASIC2-like” in DRG
neurons [9], indicating that its effect could be specific.
However, because H
+-gated currents in DRG neurons
are likely to be caused by the combination of two or
more ASIC subunits coassembled as heteromultimers,
with a coexistence of multiple channel populations
within the same cell [36,37], it is not possible to ascer-
tain its selectivity.
Thalassiolin B acts in the same range of potency in
DRG neurons (IC50 = 27.3 ± 2.6 μM) as A-317567 and
amiloride. Both produce a concentration-dependent
inhibition of ASIC currents with an IC50 ranging
between 2 and 29 μM and 30 and 51 μM in acutely dis-
sociated DRG neurons [9]. Their inhibitory action is
similar to that of streptomycin (32 ± 2.7 μM), neomycin
(44 ± 2.6 μM) [20], amiloride (30 to 51 μM), and
A-317567 (2 to 29 μM) [9]. In contrast, APETx-2 (from
the sea anemone Anthopleura elegantissima) in primary-
cultured sensory neurons inhibits ASIC3-like currents
with an IC50 of 216 nM [38], whereas psalmotoxin 1
(PcTx1, from the tarantula Psalmopoeus cambridgei)
seems to be the most potent and inhibits a subpopula-
tion of H
+-gated currents (ASIC1a-like) in DRG neurons
with an IC50 =0 . 7n M[ 3 9 ] .S i m i l a rt oP c T x 1a n d
APETx2 and in contrast with low-molecular-weight
compounds of nonpeptidic nature, amiloride and
A-317467 [9], thalassiolin B shows an effect that
depends on the application schedule, and it needs to be
applied a few seconds before the pH change, suggesting
a complex interaction with the ASICs.
For its mechanism of action, thalassiolin B has a selec-
tive action among the different ASIC channel subunits
sparing those currents with a τ ≥ 400 ms. The pH cur-
rent curve shows that thalassiolin B did not modify the
proton gating of the ASICs in DRG neurons. The
steady-state desensitizationc u r v e sa l s oi n d i c a t et h a ti t s
action is not modified by channel desensitization. The
effect of thalassiolin B shows no dependence on the pH
used to activate the ASIC current, thus indicating that
no conformational changes of the molecule as a func-
tion of pH are taking place. Interestingly, the coapplica-
tion of amiloride occluded the effect of thalassiolin B
thus suggesting that they act through a similar mechan-
ism or that the action of amiloride is downstream from
thalassiolin B. Our data shows no voltage dependence of
its effect indicating that most probably it is not entering
into the membrane field potential. It requires preappli-
cation to have a consistent inhibitory effect and it is
able only to partially block the ASIC currents (about
3 0 %a ti t sh i g h e s tc o n c e n t r a t i o n s ) ,t h u ss u g g e s t i n gt h a t
thalassiolin B is not an ASIC-pore blocker. Future stu-
dies using heterologous expression of ASIC subunits
would contribute to define the selectivity and action
mechanism of thalassiolin B on the ASICs.
Conclusions
The results of this study demonstrate the antinocicep-
tive action of the T. testudinum extract, BM-21, after a
single oral administration in classical thermal- and che-
mical caused pain in mice. The antinociceptive effects of
BM-21 may be partially caused by its antagonism to
ASIC channels. Thalassiolin B, the major phenolic con-
stituent isolated from BM-21 also had an antinociceptive
behavior in the formalin test and inhibited ASIC cur-
rents in DRG neurons indicating that this sulphated fla-
vone glycoside may be responsible, at least in part, for
the effects found with BM-21.
To our knowledge, this is the first report of the pre-
sence of an ASIC inhibitor in a marine-plant extract
and associated to an identified phenolic compound. In
comparison with other natural substances of peptidic
nature with antinociceptive action such as PcTx1 and
APETx2, the nonpeptidic nature of thalassiolin B may
have an advantage for future therapeutic applications in
the control of pain. However, further studies are still
required to ascertain its selectivity within ASIC subu-
nits, and to determine its potency, the time required to
attain therapeutic levels in vivo, and its mechanism of
action.
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